Cabio Biotech Wuhan Co Ltd - Asset Resilience Ratio
Cabio Biotech Wuhan Co Ltd (688089) has an Asset Resilience Ratio of 3.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Cabio Biotech Wuhan Co Ltd's Asset Resilience Ratio has changed over time. Check 688089 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cabio Biotech Wuhan Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Cabio Biotech Wuhan Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥65.70 Million | 3.6% |
| Total Liquid Assets | CN¥65.70 Million | 3.60% |
Asset Resilience Insights
- Limited Liquidity: Cabio Biotech Wuhan Co Ltd maintains only 3.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cabio Biotech Wuhan Co Ltd Industry Peers by Asset Resilience Ratio
Compare Cabio Biotech Wuhan Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Cabio Biotech Wuhan Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Cabio Biotech Wuhan Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥31.39K ≈ $4.59K |
CN¥1.69 Billion ≈ $246.83 Million |
0.00pp |
| 2023-12-31 | 0.00% | CN¥31.04K ≈ $4.54K |
CN¥1.61 Billion ≈ $235.81 Million |
-2.03pp |
| 2022-12-31 | 2.04% | CN¥32.80 Million ≈ $4.80 Million |
CN¥1.61 Billion ≈ $235.71 Million |
+1.24pp |
| 2021-12-31 | 0.79% | CN¥11.50 Million ≈ $1.68 Million |
CN¥1.45 Billion ≈ $211.96 Million |
-0.18pp |
| 2020-12-31 | 0.98% | CN¥13.52 Million ≈ $1.98 Million |
CN¥1.38 Billion ≈ $202.35 Million |
-- |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.